Kestra Medical develops wearable cardioverter defibrillators (WCDs) for patients at risk of sudden cardiac arrest (SCA), particularly those with heart failure or low left ventricular ejection fraction.

Kestra Medical

At Kestra, we stand for patients at-risk and the people who care for them. Together we work to protect, support, and empower them with wearable technologies, tools, and better answers as they navigate life’s most challenging medical events.

Cardiovascular disease is the number one cause of death globally. We’re taking a fresh approach to cardiac monitoring and delivery of definitive therapy with wearable products and applications. We aim to make the entire recovery process easier for patients by bringing comfort and assurance to them—along with advanced clinical insights and tools to their medical care teams.

Kestra is a privately held, Bain Capital portfolio company, headquartered in Kirkland, Washington  USA. 

Visit us at www.kestramedical.com



Bain Capital Life Sciences

Kestra Medical Technologies, Inc.

“I am on a volunteer fire department. I am used to going, and saving, and defending people’s property with a fire hose. And now I am on this end. It’s overwhelming.”
 
Watch now to hear the emotional story of Randy Rohn, a volunteer firefighter who got a second shot at life thanks to a life-saving shock from his ASSURE System.

The ASSURE system–designed for REAL bodies.

The ASSURE Assist service offers patients post shock support1

When the ASSURE system delivers a shock for a life-threatening heart rhythm, the ASSURE Assist® service is designed to send an alert via the ASSURE patient app to an Emergency Medical Services (EMS) operator.

The EMS operator attempts to contact the patient to determine if additional help is needed. If the patient cannot be reached, the EMS operator attempts to call the emergency contact and share the patient’s status and current location.

If both the patient and emergency contact cannot be reached or if either request additional help, EMS may be dispatched to the patient’s location.



1 The ASSURE Assist service requires the mobile device with the ASSURE patient app to be connected to the Internet and or Wi-Fi®, powered on, location services enabled with location permissions granted and within 30 feet of the ASSURE system for proper operation. In the event of an emergency, the ASSURE Patient App is not a substitute for appropriate medical attention and should not be relied on to contact emergency services. Kestra Medical Technologies Inc. (KMT) does not represent or warrant that the ASSURE Assist service prevents death, bodily or personal injury, or damage to you. KMT makes no representation of warranty as to the promptness of the ASSURE Assist service or emergency services. See important information about your ASSURE system at kestramedical.com/patients or the ASSURE Patient Application User Manual for a full explanation of service conditions and requirements.

A few weeks back at #HRS2024, Kestra premiered our abstract, Compliance and False Shock Alarm Rate of a Novel Wearable Cardioverter Defibrillator, showcasing a snapshot of the ASSURE WCD Registry results: 

- 94.1% of patients never experienced a false alarm
- 23.1 hrs/day median daily use 
- 87% of females chose to wear Garment B (median daily use 23.4 hrs/day)

Thank you to our co-authors: Dr. Ulrika M. Birgersdotter-Green, MD, Dr. Marye J. Gleva, MD, Dr. Kelley R. Branch, MD, Rahul Doshi, MD, and Jeanne E. Poole, MD.

And the good news keeps coming! Kestra is excited to announce that veteran medical device executive Raymond W. Cohen has been appointed to our board of directors. Mr. Cohen brings a wealth of experience and knowledge that will help drive the Kestra mission forward 💛
#HealthcareInnovation #PatientCare #MedTech
 
Read more now: https://lnkd.in/gDWWiV-D

KEST

COM:KESTRAMEDICAL

Kestra Medical